Back to Results

Edwards Lifesciences Corp (EW)

Edwards Lifesciences Corp is a healthcare company focused on products and technologies for advanced cardiovascular disease. Its portfolio includes transcatheter heart valve replacement systems for minimally invasive aortic valve replacement, marketed under the Edwards SAPIEN family, as well as transcatheter repair and replacement solutions for mitral and tricuspid valve conditions, including PASCAL and EVOQUE. The company also develops surgical structural heart products such as the INSPIRIS aortic valve, INSPIRIS RESILIA aortic valve, KONECT RESILIA conduit, and MITRIS RESILIA valve. Edwards Lifesciences sells its products through a direct sales force and independent distributors. Founded in 1958, the company is headquartered in Irvine, California, and operates in the United States, Europe, Japan, and other international markets.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-EW
$86.33
3.0% Upside
Fair
$99
18.1% Upside
Undervalued
Good
—
—
—
0.0%
July 23, 2026
44.9x
4.7x
7.7x
48.943 B
45.315 B
1.4%
99.7%
13.5
—
101.3%
Valuation • Fair Value

Edwards Lifesciences Corp (NYSE-EW) Fair Value by Valuation Model

Compare the primary fair value estimate for Edwards Lifesciences Corp (NYSE-EW) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$86.33

Estimated upside of 3.0% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$90.26

Discounted cash flow valuation reference.

Ben Graham Formula Value

$20.73

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

$51.32

Earnings power value estimate.

Comps Fair Value

$88.23

Comparable-company valuation reference.

Analyst Price Target

$99

Analysts imply upside of 18.1%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Edwards Lifesciences Corp (NYSE-EW) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Edwards Lifesciences Corp (NYSE-EW)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

6.303 B

Current operating scale indicator.

Revenue Forecast

6.747 B

Forward revenue estimate.

EBITDA

1.904 B

Current operating profitability reference.

EBITDA Forecast

2.122 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Edwards Lifesciences Corp (NYSE-EW) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Edwards Lifesciences Corp (NYSE-EW)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Good

Positive financial-health read.

Piotroski Score

5

Mid-range quality score.

Beneish M-Score

-2.42

No elevated caution signal from this screen.

Altman Z-Score

13.5

Relatively strong balance-sheet zone.

FCF / Net Income

101.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Edwards Lifesciences Corp (NYSE-EW). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Edwards Lifesciences Corp (NYSE-EW)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

July 23, 2026

Days to Earnings

2

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Edwards Lifesciences Corp (NYSE-EW), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Edwards Lifesciences Corp (NYSE-EW) Stock Forecast & Technical Outlook

Review Edwards Lifesciences Corp (NYSE-EW) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Edwards Lifesciences Corp (NYSE-EW) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Edwards Lifesciences Corp (NYSE-EW) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Edwards Lifesciences Corp (NYSE-EW) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Neutral

The weekly technical read for Edwards Lifesciences Corp (NYSE-EW) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Edwards Lifesciences Corp (NYSE-EW) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Edwards Lifesciences Corp (NYSE-EW)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Buy

Based on the available recommendation mix, Edwards Lifesciences Corp (NYSE-EW) has a Buy consensus, with 16 buy, 8 hold and 0 sell recommendations in the current data set.

Buy 16
Hold 8
Sell 0
FAQ • Fast Investor Answers

Edwards Lifesciences Corp (NYSE-EW) Stock FAQ

Quick answers about Edwards Lifesciences Corp (NYSE-EW) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$86.33
Estimated upside 3.0%
Valuation Rating
Undervalued
Estimated upside of 3.0%
Analyst Target
$99
Implied upside 18.1%
Financial Health
Good
Current financial-health read

The current fair value estimate for Edwards Lifesciences Corp (NYSE-EW) is $86.33. This implies an estimated upside of 3.0% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 3.0% versus the current market price.

The available analyst price target for Edwards Lifesciences Corp (NYSE-EW) is $99. The analyst target implies estimated upside of 18.1%.

The current financial health read for Edwards Lifesciences Corp (NYSE-EW) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Edwards Lifesciences Corp (NYSE-EW) is July 23, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Edwards Lifesciences Corp (NYSE-EW) is 44.9x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Edwards Lifesciences Corp is 48.943 B.

The current enterprise value listed for Edwards Lifesciences Corp is 45.315 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Edwards Lifesciences Corp is NYSE-EW, and the stock is listed on NYSE.

Edwards Lifesciences Corp (NYSE-EW) is listed on NYSE.

The current debt-to-total-capital ratio listed for Edwards Lifesciences Corp is 1.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Edwards Lifesciences Corp is 99.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks on NYSE View more

Abbott Laboratories (ABT) Abbott Laboratories (ABT)
Stryker Corporation (SYK) Stryker Corporation (SYK)
Medtronic PLC (MDT) Medtronic PLC (MDT)
Boston Scientific Corp (BSX) Boston Scientific Corp (BSX)
Becton Dickinson and Co (BDX) Becton Dickinson and Co (BDX)
Alcon AG (ALC) Alcon AG (ALC)
ResMed Inc (RMD) ResMed Inc (RMD)
Koninklijke Philips NV ADR (PHG) Koninklijke Philips NV ADR (PHG)
STERIS plc (STE) STERIS plc (STE)
Zimmer Biomet Holdings Inc (ZBH) Zimmer Biomet Holdings Inc (ZBH)
Solventum Corp (SOLV) Solventum Corp (SOLV)
Smith & Nephew SNATS Inc (SNN) Smith & Nephew SNATS Inc (SNN)
Penumbra Inc (PEN) Penumbra Inc (PEN)
Baxter International Inc (BAX) Baxter International Inc (BAX)
Globus Medical (GMED) Globus Medical (GMED)
Glaukos Corp (GKOS) Glaukos Corp (GKOS)
Teleflex Incorporated (TFX) Teleflex Incorporated (TFX)
Bausch + Lomb Corp (BLCO) Bausch + Lomb Corp (BLCO)
Envista Holdings Corp (NVST) Envista Holdings Corp (NVST)
Haemonetics Corporation (HAE) Haemonetics Corporation (HAE)
Integer Holdings Corp (ITGR) Integer Holdings Corp (ITGR)
Butterfly Network, Inc (BFLY) Butterfly Network, Inc (BFLY)
Enovis Corp (ENOV) Enovis Corp (ENOV)
Inspire Medical Systems Inc (INSP) Inspire Medical Systems Inc (INSP)